Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10147/221115
Title:
Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer.
Authors:
Hedden, Lindsay; O'Reilly, Susan; Lohrisch, Caroline; Chia, Stephen; Speers, Caroline; Kovacic, Laurel; Taylor, Suzanne; Peacock, Stuart
Affiliation:
Canadian Centre for Applied Research in Cancer Control, Vancouver, BC, V5Z 1L3 Canada.
Citation:
Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer. 2012, 17 (2):164-71 Oncologist
Journal:
The oncologist
Issue Date:
2012
URI:
http://hdl.handle.net/10147/221115
DOI:
10.1634/theoncologist.2011-0379
PubMed ID:
22302231
Abstract:
Among women with surgically removed, high-risk HER-2/neu-positive breast cancer, trastuzumab has demonstrated significant improvements in disease-free and overall survival. The objective of this study is to evaluate the cost-effectiveness of the currently recommended 12-month adjuvant protocol of trastuzumab using a Markov modeling approach and real-world cost data.; A 10-health-state Markov model tracked patients' quarterly transitions between health states in the local and advanced states of breast cancer. Clinical data were obtained from the joint analysis of the National Surgical Adjuvant Breast and Bowel Project and North Central Cancer Treatment Group, as well as from the metastatic study conducted by Norum et al. Clinical outcomes were adjusted for quality of life using utility estimates published in a systematic review. Real cost data were obtained from the British Columbia Cancer Agency and were evaluated from a payer perspective. Costs and utilities were discounted at 5% per year, respectively, for a 28-year time horizon.; In the base case analysis, treatment with a 12-month adjuvant trastuzumab regimen resulted in a gain of 1.38 quality-adjusted life years or 1.17 life years gained at a cost of $18,133 per patient. Thus, the cost per QALY gained for the base case is $13,095. Cost per LYG is $15,492.; Over the long term, treatment of HER-2/neu mutation positive breast cancer with a 12-month protocol of trastuzumab in the adjuvant setting is predicted to be cost-effective in a Canadian context.
Item Type:
Article
Language:
en
ISSN:
1549-490X

Full metadata record

DC FieldValue Language
dc.contributor.authorHedden, Lindsayen_GB
dc.contributor.authorO'Reilly, Susanen_GB
dc.contributor.authorLohrisch, Carolineen_GB
dc.contributor.authorChia, Stephenen_GB
dc.contributor.authorSpeers, Carolineen_GB
dc.contributor.authorKovacic, Laurelen_GB
dc.contributor.authorTaylor, Suzanneen_GB
dc.contributor.authorPeacock, Stuarten_GB
dc.date.accessioned2012-04-30T11:43:05Z-
dc.date.available2012-04-30T11:43:05Z-
dc.date.issued2012-
dc.identifier.citationAssessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer. 2012, 17 (2):164-71 Oncologisten_GB
dc.identifier.issn1549-490X-
dc.identifier.pmid22302231-
dc.identifier.doi10.1634/theoncologist.2011-0379-
dc.identifier.urihttp://hdl.handle.net/10147/221115-
dc.description.abstractAmong women with surgically removed, high-risk HER-2/neu-positive breast cancer, trastuzumab has demonstrated significant improvements in disease-free and overall survival. The objective of this study is to evaluate the cost-effectiveness of the currently recommended 12-month adjuvant protocol of trastuzumab using a Markov modeling approach and real-world cost data.-
dc.description.abstractA 10-health-state Markov model tracked patients' quarterly transitions between health states in the local and advanced states of breast cancer. Clinical data were obtained from the joint analysis of the National Surgical Adjuvant Breast and Bowel Project and North Central Cancer Treatment Group, as well as from the metastatic study conducted by Norum et al. Clinical outcomes were adjusted for quality of life using utility estimates published in a systematic review. Real cost data were obtained from the British Columbia Cancer Agency and were evaluated from a payer perspective. Costs and utilities were discounted at 5% per year, respectively, for a 28-year time horizon.-
dc.description.abstractIn the base case analysis, treatment with a 12-month adjuvant trastuzumab regimen resulted in a gain of 1.38 quality-adjusted life years or 1.17 life years gained at a cost of $18,133 per patient. Thus, the cost per QALY gained for the base case is $13,095. Cost per LYG is $15,492.-
dc.description.abstractOver the long term, treatment of HER-2/neu mutation positive breast cancer with a 12-month protocol of trastuzumab in the adjuvant setting is predicted to be cost-effective in a Canadian context.-
dc.language.isoenen
dc.rightsArchived with thanks to The oncologisten_GB
dc.titleAssessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer.en_GB
dc.typeArticleen
dc.contributor.departmentCanadian Centre for Applied Research in Cancer Control, Vancouver, BC, V5Z 1L3 Canada.en_GB
dc.identifier.journalThe oncologisten_GB

Related articles on PubMed

All Items in Lenus,the Irish health repository are protected by copyright, with all rights reserved, unless otherwise indicated.